ClinicalTrials.gg
Active, not recruitingNCT06291376I CANUpdated Oct 2, 2026

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

A Phase 3 interventional study of Ravulizumab and Placebo in Immunoglobulin A Nephropathy and IgAN, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 246 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Oct 2, 2026Study completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
584
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
5th of 67
584 · median 67
Started
2024
with 5 others
Phase 3
21 of 73
8 open now
Primary completion
2026-01
later than 3 of 36 live
Registered
46th of 73
by date
Lead sponsor
4 of 73
Alexion Pharmaceuticals, Inc.

Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 5th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2024, is one of 21 in phase 3, reaches primary completion later than 3 of the 36 other live ones, and was the 46th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Read the detailed description

The I CAN study will enroll approximately 510 eligible participants with IgAN who are high risk of disease progression. Participants will be on stable concomitant IgAN treatment(s) consistent with standard of care for patients with IgAN for at least 3 months prior to Screening. Approximately 450 participants will be randomized in a 1:1 allocation ratio to receive a weight-based IV infusion of either ravulizumab or placebo. An interim analysis may be conducted at Week 34 to evaluate change in proteinuria and the final analysis will be conducted at Week 106 to evaluate eGFR. In addition, approximately 60 participants with eGFR 20-29 mL/min/1.73m2 will be enrolled in an Advanced Kidney Disease (AdKD) Cohort. After Week 106, all participants have the option to enter an Open-label Ravulizumab Access Period.

03

Conditions studied

  • Immunoglobulin A Nephropathy
  • IgAN

Keywords

  • Immunoglobulin A nephropathy
  • IgAN
  • proteinuria
  • glomerulonephropathy
  • chronic kidney disease
  • CKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documentation of IgAN diagnosis established on kidney obtained any time prior to or during the Screening Period for participants with ≥ 30 mL/min/1.73 m\^2.
  • For participants in the AdKD cohorts, eGFR 20 to 29 mL/min/1.73 m2 a kidney biopsy is required within 6 months prior to Screening or during the Screening Period.
  • UPCR ≥ 0.75 g/g or UP ≥1 g/day calculated from the mean of two 24-hour urine during the Screening Period.
  • Estimated GFR ≥ 30 mL/min/1.73 m2 at Screening.
  • Stable and maximum allowed or tolerated RAASI (ACEI and/or ARB) dose for ≥ 3 months prior to Screening with no planned change during Screening through Week 106.
  • Participants who are receiving SGLT2I, DEARA, MRA or ERA must be on a stable and maximum allowed or tolerated dose for ≥ 3 months prior to Screening with no planned change in dose through Week 106.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of rapid progressive glomerulonephritis as measured by loss ≥ 50% over a period of 3 months prior to Screening.
  • Secondary IgAN (eg, due to systemic lupus erythematosus (SLE), cirrhosis, or celiac disease; IgAV-N may be eligible).
  • Concomitant renal disease other than IgAN.
  • Prior use of treatment within 3 months of screening.
  • Uncontrolled diabetes mellitus with glycosylated () > 8.5%.
  • Henoch-Schonlein purpura (IgAV) requiring systemic immunosuppressive therapy within 12 months of Screening.
  • History of kidney transplant or planned kidney transplant during the Treatment Period.
  • Splenectomy or functional asplenia.
  • History of Neisseria meningitidis infection.
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
584 participants (actual)

Study arms

  • Experimental
    Ravulizumab IV q8w

    Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered every 8 weeks (q8w).

    Drug: Ravulizumab

  • Placebo comparator
    Placebo IV q8w

    Participants will receive a weight-based loading dose on Day 1 followed by weight-based maintenance dosing initiated on Day 15, and then administered q8w.

    Drug: Placebo

Interventions

  • Participants will receive ravulizumab via weight-based intravenous (IV) infusion.

  • DrugPlacebo

    Participants will receive placebo via weight-based IV infusion.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR) at Week 34

    Evaluated at interim analysis only

    Time frame: Baseline, Week 34

  2. Change from Baseline in Glomerular Filtration Rate (eGFR) at Week 106

    Evaluated at final analysis only

    Time frame: Baseline, Week 106

Secondary outcomes

  1. Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR) at Weeks 10, 26, 34, 50, and 106

    Evaluated at interim and final analysis

    Time frame: Baseline, Weeks 10, 26, 34, 50, and 106

  2. Change From Baseline in eGFR at Weeks 34 and 50

    Evaluated at interim and final analysis

    Time frame: Baseline, Weeks 34 and 50

  3. Change From Baseline in Albuminuria at Each Scheduled Visit Up to Week 106

    Evaluated at interim and final analysis

    Time frame: Baseline, at Each Scheduled Visit Up to Week 106

  4. Reduction in 24-hour UPCR ≥ 50% From Baseline at Each Scheduled Visit Up to Week 106

    Evaluated at interim and final analysis

    Time frame: Baseline, at Each Scheduled Visit Up to Week 106

  5. Number of Participants With Partial Remission at Each Scheduled Visit Up to Week 106

    Evaluated at interim and final analysis

    Time frame: Baseline, at Each Scheduled Visit Up to Week 106

  6. Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Weeks 34, 50, and 106

    Evaluated at interim and final analysis

    Time frame: Baseline, Weeks 34, 50, and 106

  7. Annualized eGFR Slope Over 50 Weeks

    Evaluated at interim analysis only

    Time frame: Baseline, Over 50 Weeks

  8. Change from Baseline in Proteinuria Based on 24-hour UPCR at Week 34 with baseline UPCR ≥ 1.5 g/g

    Evaluated at final analysis only

    Time frame: Baseline Up to Week 34

  9. Change from Baseline in Proteinuria Based on 24-hour UPCR at Week 34 in Participants with Baseline UPCR ≥ 1.5 g/g and Presence of Hematuria at Baseline

    Evaluated at final analysis only

    Time frame: Baseline Up to Week 34

  10. Change from Baseline in eGFR at Week 106 in Participants with Baseline UPCR ≥ 1.5 g/g

    Evaluated at final analysis only

    Time frame: Baseline Up to Week 106

  11. Time to Sustained ≥ 30% eGFR Decline Up to Week 106

    Evaluated at final analysis only

    Time frame: Baseline Up to Week 106

  12. Time to Sustained eGFR Decline ≥ 40% Up to Week 106

    Evaluated at final analysis only

    Time frame: Baseline Up to Week 106

  13. Time to First Composite Kidney Event Up to Week 106

    Composite kidney event endpoint is defined as reaching at least 1 of the following: Sustained ≥ 30% decline in eGFR relative to baseline; or Sustained eGFR \< 15 milliliter (mL)/minute (min)/1.73 square meter (m\^2); or Maintenance dialysis; or Receipt of kidney transplant; or Death from kidney failure. Evaluated at final analysis only

    Time frame: Baseline Up to Week 106

  14. Use of Alternative IgAN Therapy Up to Week 106

    Evaluated at final analysis only

    Time frame: Baseline, Up to Week 106

07

Study locations

246 sites
  • Research Site
    Alabaster, Alabama 35007, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Bernardino, California 92408, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Valencia, California 91355, United States
  • Research Site
    Bay Pines, Florida 33744, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Acworth, Georgia 30101, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Lawrenceville, Georgia 30046, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Worcester, Massachusetts 01655, United States
  • Research Site
    Minneapolis, Minnesota 55435, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    North Las Vegas, Nevada 89086, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    The Bronx, New York 10468, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Arlington, Texas 76002, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Shenandoah, Texas 77384, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Ciudad de Buenos Aires, C1015ABO, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1425AGC, Argentina
  • Research Site
    Córdoba, X5016KET, Argentina
  • Research Site
    La Plata, B1902COS, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Canberra, 2605, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Concord, 2139, Australia
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Liverpool, 2170, Australia
  • Research Site
    Perth, 6000, Australia
  • Research Site
    Southport, 4222, Australia
  • Research Site
    St Albans, 3021, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Belo Horizonte, 30110-934, Brazil
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Curitiba, 80440-020, Brazil
  • Research Site
    Fortaleza, 60430-270, Brazil
  • Research Site
    Recife, 50670-901, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 04038-002, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Winnipeg, Manitoba R2V 3M3, Canada
  • Research Site
    Brampton, Ontario L6T 0H9, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Toronto, Ontario M5G 2C4, Canada
  • Research Site
    Araucania, 4781151, Chile
  • Research Site
    Providencia, 7500000, Chile
  • Research Site
    Santiago, 7500922, Chile
  • Research Site
    Santiago, 8330034, Chile
  • Research Site
    Valdivia, 5090146, Chile
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changzhou, 272100, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400010, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Jinhua, 321000, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Luoyang, 471000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanjing, 210011, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Qingdao, 110016, China
  • Research Site
    Shanghai, 200025, China

Showing the first 100 of 246 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Perez Valdivia MA, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25. PubMed 39455063 ↗

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jan 2026, 21 months.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 4, 2024
StartActual
Mar 29, 2024
Primary completionActual
Jan 5, 2026
CompletionEst.
Jul 18, 2030
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jul 19, 2030→Jul 18, 2030
Oct 2, 2026
Enrollment
579→584
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Study completion Jul 19, 2030→Jul 18, 2030
    Enrollment 579→584
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06291376
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Mar 29, 2024
Primary completion
Jan 5, 2026
Completion
Jul 18, 2030 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion